Daisy

Daisy

Each package Daisy it consists of 21 tablets: each tablet contains desogestrel (chamomile) (progestin) 150 mcg and Ethinylestradiol (chamomile) (one estrogen) 20 mcg.

An indication is a term used for a list of conditions or symptoms or diseases for which a medication is prescribed or used by a patient. For example, acetaminophen or acetaminophen is used by the patient for fever, or the doctor prescribes it for headaches or body aches. Now fever, headache, and body aches are indications for acetaminophen. The patient should be aware of the indications of medications used for common diseases, as they can be taken without a prescription by a doctor at a pharmacy or without a prescription.

Desogestrel (Daisy) and ethinylestradiol tablets, USP and ethinylestradiol tablets, USP are indicated to prevent pregnancy in women who use this product as a method of contraception.

Oral contraceptives are very effective. Table II lists the typical rates of emergency pregnancy for users of oral combined contraceptives and other methods of contraception. The effectiveness of these methods of contraception, with the exception of sterilization, depends on the reliability with which they are used. The correct and consistent application of these methods can lead to a lower failure rate.

Desogestrel (Daisy) and the combination of ethinyl estradiol is used to prevent pregnancy. It is a birth control pill containing two types of hormones: desogestrel (chamomile) and ethinylestradiol, and prevents pregnancy when taken correctly. It works by preventing a woman's egg from fully developing every month. The egg can no longer absorb the sperm, and fertilization is prevented.

No method of contraception is 100 percent effective. Birth control methods, such as surgery to become sterile or not to have sex, are more effective than birth control pills. Discuss your birth control options with your doctor.

Desogestrel (daisy) and ethinyl estradiol do not prevent HIV infection or other sexually transmitted diseases. It does not help as an emergency contraception, as after unprotected sexual contact.

Desogestrel (chamomile) and ethinylestradiol are only available as prescribed by a doctor.

To achieve maximum contraceptive effect, Daisy ® tablets (desogestrel (daisy)/ethinylestradiol) should be taken daily at the same time and at intervals of no more than 24 hours, as indicated. Daisy® can be launched with either a Sunday start or a day 1 launch.

NOTE: Each cycle pack dispenser is pre-printed with the days of the week starting on Sunday to facilitate the Sunday launch scheme. Six different "day label strips" are provided with each cycle pack dispenser to enable Day 1 launch mode. In this case, the patient should place a self-adhesive "day label strip" corresponding to her starting day above the pre-printed days.

DURING THE FIRST CYCLE OF USE

IMPORTANT: you should consider the possibility of ovulation and conception before using Daisy®. A woman can start taking Daisy® either on the first Sunday after the start of her menstrual cycle (beginning Sunday) or on the first day of her menstrual cycle (beginning day 1). When switching from another oral contraceptive, Daisy® should be launched on the same day that a new package of the previous oral contraceptive would have been launched.

BEGINNING OF SUNDAY

If you are starting a Sunday launch regimen, you should use a different method of contraception, such as condoms or spermicide, for the first 7 consecutive days of taking Daisy®.

At the beginning of Sunday, the tablets are taken daily without interruption as follows: the first light yellow tablet should be taken on the first Sunday after the start of menstruation (if menstruation begins on Sunday, the first light yellow tablet is taken on this day). Then the pills are taken one by one according to the arrows marked on the donor. A light yellow tablet is taken daily for 7 days, followed by 1 orange tablet daily for 7 days, 1 red tablet daily for 7 days, and then 1 green (inactive) tablet daily for 7 days. For all subsequent cycles, the patient begins a new 28-tablet regimen on the next day (Sunday) after taking the last green (inactive) tablet. [When switching from an oral contraceptive at the beginning of Sunday, the first Daisy® tablet (desogestrel (Daisy)/ethinylestradiol) should be taken on the second Sunday after the last tablet of the 21-day oral contraceptive or on the first Sunday after the last inactive tablet of the 28-day contraceptive.]

If a patient misses 1 active tablet for 1, 2, or 3 weeks, she should take the missed tablet as soon as she remembers it. If the patient skips 2 consecutive active tablets in Week 1 or week 2, the patient should take 2 tablets on the day he remembers and 2 tablets the next day, after which the patient should take 1 tablet a day until he finishes the cycle. The patient should be instructed to use a backup method of birth control (such as condoms or spermicide) if she has sexual intercourse within 7 days of reloading her pills. If the patient skips 2 consecutive red (active) tablets in the third week, or skips 3 or more active tablets in a row during the cycle, the patient should take 1 active tablet a day until the following Sunday. On Sunday, the patient should discard the rest of this cycle package and start a new cycle package on the same day. The patient should be instructed to apply the backup method of birth control if she has sexual intercourse within 7 days after the restart

For full instructions on facilitating patient consultation on the correct use of the pill, see In a detailed or brief inscription of the patient (section " How to take the pill?").

DAY 1 START

If you consider the first day of menstruation as "day 1", then the first light yellow tablet should be taken on the first day of menstrual bleeding. Then the tablets are taken one by one without interruption as follows: one light yellow tablet daily for 7 days, then 1 orange tablet daily for 7 days, then 1 red tablet daily for 7 days, and then 1 green (inactive) tablet daily for 7 days. For all subsequent cycles, the patient begins a new 28-tablet regimen the day after taking the last green (inactive) tablet. [In the case of a direct transfer from another oral contraceptive, the first light yellow pill should be taken on the same day that a new package of the previous oral contraceptive would have been started.]

If a patient misses 1 active tablet for 1, 2, or 3 weeks, she should take the missed tablet as soon as she remembers it. If the patient skips 2 consecutive active tablets in Week 1 or week 2, the patient should take 2 tablets on the day he remembers and 2 tablets the next day, after which the patient should take 1 tablet a day until he finishes the cycle. The patient should be instructed to use a backup method of birth control (such as condoms or spermicide) if she has sexual intercourse within 7 days of reloading her pills. If the patient missed 2 consecutive red tablets in the third week, or missed 3 or more active tablets in a row at any point during the cycle, the patient should discard the rest of this cycle package and start a new cycle package on the same day. The patient should be instructed to apply the backup method of birth control if she has sexual intercourse within 7 days after the restart

For full instructions on facilitating patient consultation on the correct use of the pill, see In a detailed or brief inscription of the patient (section " How to take the pill?").

ADDITIONAL INSTRUCTIONS FOR Sunday AND DAY 1 BEGINS

Breakthrough bleeding, spots, and amenorrhea are common causes for patients who stop oral contraceptives. In the case of breakthrough bleeding, as in all cases of irregular bleeding from the vagina, non-functional causes should be taken into account. In undiagnosed persistent or recurrent abnormal vaginal bleeding, adequate diagnostic measures are indicated to rule out pregnancy or malignancy. If both pregnancy and pathology have been ruled out, timing or changing another drug may solve the problem.. Switching to an oral contraceptive with a higher estrogen content, which may be useful for minimizing menstrual disorders, should only be done when necessary, as this may increase the risk of thromboembolic disease

Daisy®Application In case of missed menstruation

1. If the patient did not follow the prescribed schedule, the possibility of pregnancy at the time of the first missed period should be considered, and the use of Daisy® should be discontinued if the pregnancy is confirmed.
2. If the patient follows the prescribed regimen and skips two consecutive periods, pregnancy should be excluded. Daisy® should be discontinued if the pregnancy is confirmed.

The use of Daisy® for contraception can be started 4-6 weeks after delivery in women who choose breastfeeding. If the tablets are administered during the postpartum phase, the increased risk of thromboembolic disease associated with the postpartum phase must be considered.

If the patient begins taking Daisy® postpartum and has not yet had a period, she should be instructed to use another method of contraception until a light yellow tablet is taken daily for 7 consecutive days.

Hypersensitivity to desogestrel (chamomile) and ethinyl estradiol (chamomile) or any of the other components of chamomile.

Combined oral contraceptives should not be used in the presence of any of the following conditions. If any of the conditions occur for the first time while using the COC, Daisy should be stopped immediately.

Presence or history of venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism), presence or history of arterial thrombosis (myocardial infarction, cerebrovascular accident) or prodromal conditions (e.g., temporary ischemic attack, angina pectoris), known predisposition to venous or arterial thrombosis, e.g., activated protein C resistance (APC), antithrombin III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and antiphospholipid antibodies, history of migraine with focal neurological symptoms, diabetes mellitus with vascular involvement.

max.

Use during pregnancy: Daisy is not shown during pregnancy. If pregnancy occurs during treatment with chamomile, further use should be discontinued. However, most epidemiological studies have found neither an increased risk of birth defects in children born to women who consumed coke before pregnancy, nor a teratogenic effect if the coke was accidentally taken during early pregnancy.

Use during breastfeeding: The lactation period can be affected by coc, as it can reduce the amount and change the composition of breast milk. Therefore, the use of coca should generally not be recommended until the nursing mother has completely weaned the baby. Small amounts of contraceptive steroids and / or their metabolites can be excreted in milk, but there is no evidence that this affects the health of infants.

Interactions between oral contraceptives and other medications can lead to breakthrough bleeding and / or oral contraceptive failure. The following twists and turns were reported in the literature.

Liver metabolism: interaction may occur with drugs that cause microsomal enzymes, which may lead to an increase in the clearance of sex hormones (for example, hydantoins, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin and products containing St. John's wort). The maximum induction of vermengt is usually not observed for 2-3 weeks, but then it can be at least 4 weeks after discontinuation of drug therapy.

Contraceptive failures have also been reported on antibiotics such as ampicillin and tetracyclines. The mechanism of this effect has not been disclosed.

Women receiving one of these medications should temporarily use a barrier method in addition to the combined oral contraceptive (COC) or choose another method of contraception. For microsomal enzyme-inducing drugs, the barrier method should be used during simultaneous administration of the drug and 28 days after its discontinuation. In the case of long-term treatment with microsomal enzyme-inducing drugs, another method of contraception should be considered. Women receiving antibiotics (with the exception of rifampicin and griseofulvin, which also act as microsomal enzyme-inducing drugs) should use the barrier method up to 7 days after discontinuation. If the period during which the barrier method is applied goes beyond the end of the tablets in the COC package, the next COC package should be started without the usual no-tablet interval

Oral contraceptives can affect the metabolism of other medications. Accordingly, plasma and tissue concentrations may either increase (e.g., cyclosporine) or decrease (e.g., lamotrigine).

Note: to identify possible interactions, consult the prescribing information of concomitant medications.

Laboratory tests: The use of contraceptive steroids may affect the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal, and kidney function, plasma protein (carrier) levels, such as corticosteroid-binding globulin and lipid/lipoprotein fractions, carbohydrate metabolism parameters, and blood clotting and fibrinolysis parameters. The changes usually remain in the normal laboratory area.

Incompatibility: not applicable.

See also:
What are the possible side effects of Daisy?

Possibly related adverse effects reported in users of Daisy or combined oral contraceptives (COC) in general are listed as follows (the most appropriate MedDRA term version 11.0 to describe a specific adverse reaction. Synonyms or related terms are not specified, but should also be taken into account): Organ system class: general (>1/100 ), speech (>1/1000 and <1/100), speech (<1/1000).

Immune system disorders: Rare: hypersensitivity.

Metabolic and nutritional disorders: sometimes: Fluid retention.

Mental disorders: often: depressive and altered mood. Unusual: decreased libido. Rarely: Increased libido.

Disorders of the nervous system: Often: headache. Sometimes: Migraine.

Eye diseases: Rare: contact lens intolerance.

Gastrointestinal diseases: common: Nausea, abdominal pain. Sometimes: Vomiting, diarrhea.

Diseases of the skin and subcutaneous tissue: occasionally: rash, urticaria. Rarely: Nodular erythema, erythema multiforme.

Diseases of the reproductive system and chest: Often: chest pain, chest clamps. Unusual: breast augmentation. Rarely: discharge from the vagina, discharge from the breast.

Studies: Often: Increased weight. Rarely: Reduced weight.

A number of side effects have been reported in women using combined oral contraceptives, which are described in more detail in the warnings and precautions. These include: venous thromboembolic disorders, arterial thromboembolic disorders, hypertension, hormone-dependent tumors (for example, liver tumors, breast cancer), chloasma, gallstone disease (formation of gallstones in the gallbladder), cholestatic jaundice.